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To the Editor,
Extra intestinal manifestations (EIM) of 
inflammatory bowel disease (IBD) have been 
reported to affect several systems including those 
cardiovascular, skin and skeletal. These manifestations 
also involve the oral cavity, with inflammation being 
a common denomination. Inflammation, in a well-
controlled immune system, is a normally exhibited 
physiological reaction in intestinal mucosa as a 
response to microbial antigens. Gastrointestinal 
microbiota is, however, very complex and rich 
in antigenic determinants. Once these offending 
agents are eliminated, the inflammation disappears. 
However, in the case of abnormal conditions and 
diseases, the inflammation persists and becomes 
chronic, thus leading to functional and anatomical 
alterations. The inflammatory bowel diseases, 
including Crohn’s disease (CD) and ulcerative 
colitis (UC), are examples of chronic relapsing 
inflammatory disorders of the gastrointestinal 
tract. IBD has wide and non-pathognomonic 
clinical characteristics which can usually mislead 
the clinician. Therefore, in addition to the clinical 
presentation, histological and radiological findings 
as well as endoscopic, serological and anatomo-
pathologic evaluations constitute important elements 
for establishing an accurate diagnosis. Recently, 
stool markers were detected and seemed helpful for 
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Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, have 
important extraintestinal manifestations, notably in the oral cavity. These oral manifestations can 
constitute important clinical clues in the diagnosis and management of IBD, and include changes at 
the immune and bacterial levels. Aphthous ulcers, pyostomatitis vegetans, cobblestoning and gingivitis 
are important oral findings frequently observed in IBD patients. Their presentations vary considerably 
and might be well diagnosed and distinguished from other oral lesions. Infections, drug side effects, 
deficiencies in some nutrients and many other diseases involved with oral manifestations should also 
be taken into account. This article discusses the most recent findings on the oral manifestations of IBD 
with a focus on bacterial modulations and immune changes. It also includes an overview on options for 
management of the oral lesions of IBD.
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and environmental factors such as smoking, diet, 
use of antibiotics or nonsteroidal anti-inflammatory 
drugs and the presence of enteric infections (2). 
It is well documented that the most widely 
accepted mechanism of IBD pathogenesis includes 
inflammation due to altered host immune response 
in association with continuous stimulation from the 
resident gut microbiota and consequent secretions 
of an array of proinflammatory entities and reactive 
oxygen species (ROS) (1). IL-6 seems to have an 
important role in the regulation of IBD chronic 
inflammatory process. The overproduction of IL-6 
by immunocompetent cells is thought to contribute 
to the development of the inflammatory condition. 
Patients with CD and UC have higher concentrations 
of IL-6 in the saliva compared to plasma. This could 
be expected and may indicate that the inflammatory 
process in the bowel causes a higher release of 
IL-6 in the saliva since the saliva-producing cells 
are greatly involved with the functions of the 
digestive tract, the inflamed organ. Further analysis 
of immunological biomarkers in the saliva of IBD 
patients showed higher levels of many inflammatory 
cytokines, immunoglobulin A, IL-1β and IL-8 as well 
as a lower lysozyme level (8). Additionally, saliva 
contains a variety of components such as cytokines, 
immunoglobulins, hormones and antimicrobial 
proteins involved in host defense mechanisms for 
maintaining oral and systemic health. Levels of many 
salivary cytokines and IgA were significantly higher 
in both CD and UC patients than those observed in 
healthy patients, documenting that inflammatory 
responses are triggered in the oral cavity of the 
patients (8). As mentioned above, increased salivary 
IL-1β, and tumor necrosis factor-α (TNF-α) levels in 
CD patients and an elevated IL-8 level in the saliva 
of patients with bowel disease were also reported 
(9). On the other hand, IBD patients demonstrate 
autoimmune changes affecting the minor salivary 
glands, leading to dry mouth (5). This results in 
significantly reduced salivary lysozyme levels 
as compared with those of healthy controls (8). 
Lysozyme is an antimicrobial protein expressed by 
various cells including epithelial cells, neutrophils 
and macrophages. It plays a major role in the host 
constitutive defense mechanisms and is abundant 
diagnosis (1). On the other hand, the oral cavity is 
a large reservoir of bacteria profoundly relevant to 
host health and disease. Current studies highlighted 
various oral symptoms such as aphthous stomatitis, 
lip swelling, oral ulcer and pyostomatitis vegetans 
(PV) that are frequently seen in IBD patients 
(2). These oral findings are manifestations of the 
underlying disease process. Since saliva-producing 
cells are part of the digestive system, the assessment 
of this body fluid was conducted in many studies. 
For instance, elevated interleukin-6 (IL-6) was found 
in saliva of patients with IBD, indicating that the 
general involvement of the gastrointestinal tract is 
extending to the oral cavity. Therefore, measuring 
IL-6 can be a convenient tool to monitor disease 
activity and progression. This minireview sheds the 
light on the oral manifestations of IBD. Relevant 
findings in the literature for the past 15 years or so 
on bacterial modulations and immune changes were 
evaluated. Management of the oral lesions of IBD is 
also covered.
Prevalence of oral manifestations in IBD
Oral lesions have been reported to occur in up to 
50% of IBD patients. They are more prevalent in CD 
patients and are more likely to occur in males and in 
children (3).  The prevalence of oral lesions in CD 
reportedly ranges from 20% to 50% (2). However, 
a recent systematic review on pediatric CD revealed 
that the prevalence of oral manifestations ranged 
between 10% and 80%, based on 28 papers published 
between 2000 and 2015 (4). On the other hand, oral 
lesions have been also reported to occur in only 8% 
of UC patients (5). Some studies, however, noted no 
statistically significant differences between the two 
diseases (6). 
Immune changes in the oral cavity
The exact pathogenesis of IBD has not been 
clearly elucidated, however, it is thought to be 
caused by a dysregulated immunity (7). Generally, 
it is assumed that IBD is a multifactorial disease 
involving the immune system (abnormal self-
recognition and autoantibodies against organ-specific 
cellular antigens shared by the gastrointestinal tract 
and other organ systems) (7), genetic susceptibility, 
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not directly associated with the activity of intestinal 
IBD (25). Mucosal tags are indurated, polypoid, 
tag-like lesions that are mainly seen in the labial 
and buccal mucosa as well as in retromolar regions. 
Mucogingivitis lesions are characterized by gingival 
redness, swelling and easy bleeding in addition to 
having a hyperplastic and edematous appearance (2). 
In a prospective 3-year study conducted by Harty et 
al., up to 60% of CD patients had mucogingivitis 
(12). Furthermore, patients usually complain of 
swelling of the face and the lips.  These lesions may 
impair proper oral function, or lead to psychological 
disorders due to disfigurement (13). Histological 
examination of these lesions typically show non-
caseous granulomatous inflammation. Many studies 
reported an increased rate of granuloma detection in 
oral biopsies, reaching up to 77% (14); granulomas 
were found in 14/16 patients biopsied in two different 
cohorts (12). In a prospective cohort study, the 
presence of oral granulomas was the most important 
diagnostic criterion used for classifying the patient 
as having CD as opposed to UC (14). 
Non-specific oral lesions associated with CD and 
UC include aphthous stomatitis, angular cheilitis, 
pyostomatitis vegetans, glossitis, halitosis, caries, 
persistent submandibular lymphadenopathy, and 
lichen planus (5, 15). 
Aphthous stomatitis presents as shallow, round 
ulcers surrounded by an erythematous border with a 
central fibrinous membrane. The lesions occur in up 
to 10% of patients with UC, and 20%-30% of those 
with CD (7). Angular cheilitis manifests as erythema 
in the presence or absence of painful fissures at the 
corners of the mouth. It can occur due to anemia or 
as a manifestation of a fungal or bacterial infection 
(5). Pyostomatitis vegetans is a rare benign chronic 
inflammatory mucocutaneous disorder characterized 
by pustules of an unknown etiology. It is the only 
condition that is more prevalent in UC patients 
compared to those with CD, and is more common in 
male patients. It represents a specific inflammatory 
marker of UC. Macroscopically, the disease manifests 
as small exophytic lesions with an erythematous 
border and a creamy white or yellow surface. The 
lesions are covered with vulnerable membranes and 
their cracking results in small superficial erosions 
in saliva. Salivary lysozyme was reported to be 
significantly lower in patients with gingivitis and 
periodontitis as compared with healthy subjects (10).
Bacterial changes in the oral cavity
Alterations in the oral microbiota were described 
among IBD patients. Analysis of salivary microbiota 
of IBD patients as compared to healthy controls 
revealed that Bacteroidetes were significantly 
increased with a concurrent decrease in Proteobacteria. 
The dominant genera, including Streptococcus, 
Prevotella, Neisseria, Haemophilus, Veillonella, and 
Gemella, were found to be significantly contributing 
to dysbiosis (dysbacteriosis) observed in the salivary 
microbiota of IBD patients. Other reports have noted 
a significant increase of the genus Prevotella in the 
salivary microbiota of IBD patients, with a relative 
abundance almost equivalent to the reduction of 
Streptococcus, the latter being most abundant in 
healthy salivary microbiota. 
It is worth noting that there was a strong 
correlation between lysozyme and IL-1β levels and 
the relative abundance of Streptococcus, Prevotella, 
Haemophilus and Veillonella (8). Interactions among 
these organisms and other species could be involved 
in the dysbiosis of salivary microbiota of IBD 
patients (11).
Oral pathologies
Oral manifestations are divided into two 
categories, specific lesions, and more commonly, 
non-specific lesions. CD is characterized by both 
specific and non-specific oral lesions, while only 
non-specific lesions are seen in UC. 
Specific oral lesions in patients with CD include 
cobblestoning of the oral mucosa, deep linear 
ulcerations, mucosal tags, mucogingivitis as well as 
face and lip swelling (5). “Cobblestoning” lesions 
present as nodular granulomatous swellings that 
affect the oral mucosa, more specifically the labial 
and the posterior part of buccal mucosa, and result in 
a cobblestone appearance. They are characterized by 
thickened, firm, and pinkish areas mostly on the labial 
and jugal mucosa, which may be multifocal, linear, 
polypoid, or diffuse. Although they are considered 
pathognomic lesions for CD, their presentation is 
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lesions. Among these, infections, drug side effects, 
deficiencies in some nutrients and many other 
diseases involved with oral manifestations should be 
taken into account. For this reason, collaboration of 
different specialists, including gastroenterologists, 
coloproctologists, dermatologists and dental experts, 
should be implemented for a better diagnosis and 
management of IBD.
While their management is usually limited to 
symptomatic treatment, some cases may require the 
use of antibiotics, steroids or immunosuppressive 
drugs. Given the fact that IBD is usually caused 
by the upregulation of expression of inflammatory 
cytokines, TGF-β, TNF-α, ROS and other signaling 
molecules leading to an imbalance in the intestinal 
microflora, further studies must focus on a treatment 
targeting this imbalance to prevent the occurrence of 
this inflammatory disease. 
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